Ani Pharmaceuticals (ANIP) Goodwill & Intangibles (2012 - 2026)

Ani Pharmaceuticals has disclosed Goodwill & Intangibles across 15 years of filings, most recently posting $529.6 million for Q1 2026.

• Goodwill & Intangibles for Q1 2026 came in at $529.6 million, down 11.6% year-over-year; the trailing twelve-month figure through Mar 2026 was $529.6 million (down 11.6% YoY), and the FY2025 annual result was $542.0 million, down 9.94% from the prior year.
• Goodwill & Intangibles came in at $529.6 million for Q1 2026 at Ani Pharmaceuticals, down from $542.0 million in the prior quarter.
• In the past five years, Goodwill & Intangibles ranged from a high of $630.3 million in Q3 2024 to a low of $32.5 million in Q2 2023.
• The 5-year median for Goodwill & Intangibles is $297.8 million (2022), against an average of $363.8 million.
• Across the five-year window, Goodwill & Intangibles slumped 89.08% in 2023 and soared 549.73% in 2024, its largest moves.
• Ani Pharmaceuticals' Goodwill & Intangibles stood at $279.8 million in 2022, then dropped by 15.23% to $237.2 million in 2023, then surged by 153.69% to $601.8 million in 2024, then decreased by 9.94% to $542.0 million in 2025, then fell by 2.28% to $529.6 million in 2026.
• The last three Goodwill & Intangibles figures came in at $529.6 million (Q1 2026), $542.0 million (Q4 2025), and $562.3 million (Q3 2025), per Business Quant data.